CLGN (CollPlant Biotechnologies) Cyclically Adjusted FCF per Share: $-0.72 (As of Mar. 2026)


CLGN CollPlant Biotechnologies Ltd CLGN
35 GF Score
Price $0.37
GF Value $0.29
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is CollPlant Biotechnologies Cyclically Adjusted FCF per Share?

CollPlant Biotechnologies CLGN +2.17% 35 Cyclically Adjusted FCF per Share is $-0.72 as of Mar. 2026. GuruFocus rates CLGN with a GF Score™ of 35/100 and a GF Value™ of $0.29 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

CollPlant Biotechnologies's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.222. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.72 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-12), CollPlant Biotechnologies's current stock price is $0.3694. CollPlant Biotechnologies's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-0.72. CollPlant Biotechnologies's Cyclically Adjusted Price-to-FCF of today is .


CollPlant Biotechnologies  (NAS:CLGN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


CollPlant Biotechnologies Cyclically Adjusted FCF per Share Related Terms


CollPlant Biotechnologies Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for CollPlant Biotechnologies's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CollPlant Biotechnologies Cyclically Adjusted FCF per Share Chart

CollPlant Biotechnologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.60 -0.67 -0.69

CollPlant Biotechnologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.68 -0.71 -0.74 -0.69 -0.72

CLGN vs CPMV, TCRT, DRMA: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, CollPlant Biotechnologies's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CollPlant Biotechnologies Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's Cyclically Adjusted Price-to-FCF falls into.


CLGN
35GF Score
CollPlant Biotechnologies Ltd CLGN
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CollPlant Biotechnologies Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CollPlant Biotechnologies's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.222/330.2130*330.2130
=-0.222

Current CPI (Mar. 2026) = 330.2130.

CollPlant Biotechnologies Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.015 241.018 -0.021
201609 -0.008 241.428 -0.011
201612 -0.009 241.432 -0.012
201703 -0.014 243.801 -0.019
201706 -0.008 244.955 -0.011
201709 -0.007 246.819 -0.009
201712 -0.439 246.524 -0.588
201803 -0.010 249.554 -0.013
201806 -0.011 251.989 -0.014
201809 -0.257 252.439 -0.336
201812 0.667 251.233 0.877
201903 -0.358 254.202 -0.465
201906 -0.454 256.143 -0.585
201909 -0.307 256.759 -0.395
201912 -0.331 256.974 -0.425
202003 -0.401 258.115 -0.513
202006 -0.276 257.797 -0.354
202009 0.137 260.280 0.174
202012 -0.250 260.474 -0.317
202103 0.953 264.877 1.188
202106 -0.358 271.696 -0.435
202109 -0.329 274.310 -0.396
202112 -0.271 278.802 -0.321
202203 -0.326 287.504 -0.374
202206 -0.392 296.311 -0.437
202209 -0.316 296.808 -0.352
202212 -0.327 296.797 -0.364
202303 -0.319 301.836 -0.349
202306 -0.347 305.109 -0.376
202309 0.571 307.789 0.613
202312 -0.225 306.746 -0.242
202403 -0.291 312.332 -0.308
202406 -0.361 314.175 -0.379
202409 -0.313 315.301 -0.328
202412 -0.308 315.605 -0.322
202503 -0.103 319.799 -0.106
202506 -0.206 322.561 -0.211
202509 -0.226 324.800 -0.230
202512 -0.231 324.054 -0.235
202603 -0.222 330.213 -0.222

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-0.72 mean?
CollPlant Biotechnologies (CLGN) has a Cyclically Adjusted FCF per Share of $-0.72 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on CollPlant Biotechnologies and its competitors.
Is CollPlant Biotechnologies' Cyclically Adjusted FCF per Share too high?
CollPlant Biotechnologies' current Cyclically Adjusted FCF per Share is $-0.72. Overall, CollPlant Biotechnologies has a GF Score™ of 35/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' Cyclically Adjusted FCF per Share compare to CPMV and TCRT?
CollPlant Biotechnologies' Cyclically Adjusted FCF per Share of $-0.72 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on CollPlant Biotechnologies and its competitors. CollPlant Biotechnologies's current Cyclically Adjusted FCF per Share is $-0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (CLGN) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.29, compared to a current price of $0.37 — trading 27.4% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $-0.72. CollPlant Biotechnologies' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For CollPlant Biotechnologies (CLGN), the current Cyclically Adjusted FCF per Share is $-0.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CollPlant Biotechnologies (CLGN) Overvalued in 2026?

Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued. The current stock price of $0.37 is trading 27.4% above its estimated GF Value™ of $0.29. GuruFocus considers CollPlant Biotechnologies to be Modestly Overvalued.

Key valuation signals for CLGN:

  • Cyclically Adjusted FCF per Share: $-0.72
  • GF Value™: $0.29 vs. price of $0.37 (27.4% above fair value)
  • GF Score™: 35/100 with 4 warning signs

No single metric tells the full story. See the CLGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CollPlant Biotechnologies Business Description

Other Exchanges CPT:Germany
Address 4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
35GF Score

Get the complete analysis for CLGN

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.37
Price
$0.29
GF Value